On May 21, 2026, Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company, revealed plans to showcase data from its off-the-shelf CAR T-cell programs at two upcoming events. The American Society of Cancer Oncology Annual Meeting in Chicago, IL from May 29 to June 2, 2026, and the European Congress of Rheumatology in London, UK from June 3 to June 6, 2026 will host presentations on the company's induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases.